GO:0031491 nucleosome binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031491 nucleosome binding is a molecular function defined as binding to a nucleosome, the fundamental DNA packaging unit composed of DNA wrapped around a histone core.
• Nucleosome binding underlies pioneer transcription factor activity, chromatin remodeling, histone modification crosstalk, and higher-order chromatin compaction [1,2,3].
• Key structural studies show that nucleosome binding induces allosteric and dynamic changes in both the nucleosome and the bound protein, influencing downstream processes such as H3K27 trimethylation and H3K56 acetylation [1,2,8].
• Dysregulation of nucleosome-binding proteins is implicated in cancer, developmental disorders, and other diseases, making these proteins attractive therapeutic targets [2,5,6].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal interrogation of nucleosome-binding proteins in disease and development.
• EDITGENE provides end-to-end services for nucleosome binding research, including custom cell model generation, CRISPR library screening, and bioinformatics analysis.
Description
Nucleosome binding (GO:0031491) is a molecular function that describes the physical interaction between a protein or protein complex and a nucleosome, the basic repeating unit of chromatin. Nucleosomes consist of approximately 147 base pairs of DNA wrapped around a histone octamer, and their dynamic interactions with nuclear proteins are central to gene regulation, DNA replication, and genome stability. Proteins that bind nucleosomes include pioneer transcription factors, chromatin remodelers, histone chaperones, and structural chromatin proteins, each recognizing specific nucleosome features such as DNA accessibility, histone tail modifications, or histone variant composition [1,2,3,4,5]. The functional importance of nucleosome binding is underscored by its role in diverse biological processes. For example, pioneer transcription factors such as TP53 and GATA3 bind nucleosomes to initiate chromatin opening and transcriptional activation [1,4,6]. The DEK protein binds nucleosomes to facilitate H3K27 trimethylation, a key epigenetic mark for gene silencing. Linker histones like H5 bind nucleosomes to promote chromatin fiber compaction. These interactions are not passive; they often induce structural and dynamic changes in the nucleosome that sensitize it to further modifications, such as H3K56 acetylation. Given the broad impact of nucleosome binding on gene expression and genome organization, researchers require robust experimental models to dissect its mechanisms and disease relevance. This article provides a comprehensive overview of GO:0031491, covering its definition, structural basis, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods, including CRISPR-based approaches and EDITGENE's specialized services.
nucleosome binding At A Glance
| GO ID | GO:0031491 |
|---|---|
| GO term | nucleosome binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to a nucleosome, the fundamental DNA packaging unit, to regulate chromatin structure and gene expression. |
| Representative proteins | Pioneer transcription factors (e.g., TP53, GATA3), chromatin structural proteins (e.g., DEK, linker histone H5), and chromatin remodelers [1,2,3,4,5,6]. |
| Structural basis | Involves recognition of histone surfaces, DNA grooves, and post-translational modifications, often inducing allosteric changes [1,2,3,4,5,8]. |
| Disease relevance | Implicated in cancers, developmental disorders, and other diseases through dysregulation of nucleosome-binding proteins [2,5,6]. |
| Research methods | Structural biology (cryo-EM, X-ray crystallography), competitive binding assays, CRISPR screens, and biochemical assays [1,2,3,4,5,6,7,8]. |
What Is GO:0031491?
Nucleosome binding (GO:0031491) is defined by the Gene Ontology as the binding to a nucleosome, a complex comprised of DNA wound around a multisubunit core and associated proteins, which forms the primary packing unit of DNA into higher order structures. In practical terms, it refers to the ability of a protein to physically associate with a nucleosome, often through interactions with the histone core, the DNA backbone, or both, and this binding can alter nucleosome stability, positioning, or accessibility.
Why Is nucleosome binding Important in Cell Biology?
Nucleosome binding is a cornerstone of chromatin biology because it governs how proteins access the genome. By binding to nucleosomes, proteins can modulate chromatin compaction, recruit histone-modifying enzymes, and influence transcription, replication, and repair [1,2,3,7]. This function is essential for normal development and cellular homeostasis, and its dysregulation is linked to a range of human diseases, including cancer and developmental syndromes [2,5,6]. Understanding nucleosome binding at the molecular level therefore provides critical insights into gene regulation and offers potential targets for therapeutic intervention.
• Regulates chromatin accessibility and gene expression by controlling nucleosome stability and positioning [1,4,6].
• Enables pioneer transcription factors to initiate chromatin opening at enhancers and promoters [1,6].
• Facilitates crosstalk with histone modifications, such as H3K27me3 and H3K56ac, impacting epigenetic inheritance [2,8].
• Drives higher-order chromatin compaction through linker histone binding.
• Plays a role in DNA damage response and genome stability by recruiting repair factors to nucleosomes.
• Dysregulation is associated with cancers, including those driven by TP53 mutations and RFX5-related disorders [5,6].
• Serves as a target for small-molecule inhibitors and degraders in epigenetic therapy [2,8].
• Provides a basis for understanding developmental disorders linked to chromatin remodeler mutations.
• Enables CRISPR-based functional genomics to identify novel nucleosome-binding proteins and their roles.
• Informs the design of engineered nucleosome-binding proteins for synthetic biology and gene therapy [1,3].
Molecular Mechanism of nucleosome binding
Recognition of Nucleosome Surface
In simple terms: Proteins find and attach to specific features on the nucleosome surface.
Nucleosome binding typically begins with the recognition of structural features on the nucleosome, such as the histone octamer surface, the DNA backbone, or specific histone tails. Pioneer transcription factors like TP53 and GATA3 engage nucleosomes through interactions with both DNA and histone proteins, often using extended DNA-binding domains [1,4,6]. Structural studies of RFX5 reveal that its extended DNA binding domain binds nucleosomal DNA and induces destabilization, facilitating subsequent chromatin remodeling. Similarly, the linker histone H5 binds to the nucleosome core and linker DNA to promote chromatin compaction.
Allosteric and Dynamic Changes in the Nucleosome
In simple terms: Binding causes the nucleosome to change shape and become more flexible.
Upon binding, proteins can induce allosteric changes in the nucleosome that alter its conformation and dynamics. For example, pioneer transcription factor binding leads to nucleosome allostery, affecting histone-DNA contacts and exposing previously buried regions. GATA3 binding causes structural and dynamic changes in the nucleosome, including altered histone tail accessibility. These changes can sensitize the nucleosome to further modifications, such as H3K56 acetylation, as shown by Lee et al..
Facilitation of Histone Modifications
In simple terms: Binding helps enzymes add chemical marks to histones.
Nucleosome-binding proteins often recruit or stabilize histone-modifying enzymes, thereby facilitating post-translational modifications. DEK binding to nucleosomes promotes H3K27 trimethylation by the PRC2 complex, a key step in gene silencing. This crosstalk between nucleosome binding and histone modification is critical for establishing and maintaining epigenetic states.
Chromatin Compaction and Higher-Order Structure
In simple terms: Binding helps pack DNA into tighter structures.
Linker histones and other structural proteins bind nucleosomes to mediate chromatin fiber compaction. The linker histone H5 binds the nucleosome and facilitates the folding of chromatin into higher-order structures, as revealed by recent structural studies. This compaction is essential for organizing the genome and regulating access to DNA.
Regulation by Post-Translational Modifications
In simple terms: Chemical tags on proteins can turn binding on or off.
Nucleosome binding can be regulated by post-translational modifications of either the binding protein or the histones. For instance, acetylation of H3K56 sensitizes the nucleosome to binding by specific proteins, as demonstrated by Lee et al.. Such modifications provide a dynamic layer of control over nucleosome interactions.
Key Genes Involved in GO:0031491 nucleosome binding
The following genes encode proteins with demonstrated nucleosome binding activity (GO:0031491) and are frequently studied in chromatin biology and disease research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Pioneer transcription factor that binds nucleosomes to initiate chromatin opening and transcriptional activation [1,6]. | Widely mutated in cancer; used to study pioneer factor function and nucleosome competition. |
| GATA3 | Transcription factor that binds nucleosomes and induces structural changes to regulate gene expression. | Implicated in breast cancer and T-cell development; model for studying nucleosome dynamics. |
| DEK | Chromatin structural protein that binds nucleosomes and facilitates H3K27 trimethylation. | Oncogene in leukemia and other cancers; target for epigenetic therapy. |
| H5 (H1-5) | Linker histone that binds nucleosomes to promote chromatin fiber compaction. | Model for studying higher-order chromatin structure and compaction. |
| RFX5 | Transcription factor with extended DNA binding domain that binds and destabilizes nucleosomes. | Mutations cause bare lymphocyte syndrome; model for nucleosome destabilization. |
| H3-3A (H3.3) | Histone variant incorporated into nucleosomes; binding by chaperones and remodelers. | Used to study histone dynamics and nucleosome composition. |
| H2A.Z | Histone variant that alters nucleosome stability and binding properties. | Implicated in gene regulation and cancer; model for variant nucleosomes. |
| H2B | Core histone that forms the nucleosome octamer; interacts with binding proteins. | Target for acetylation studies (e.g., H3K56ac). |
| H4 | Core histone; its modifications affect nucleosome binding. | Used in structural and biochemical studies of nucleosome interactions. |
| CHD1 | Chromatin remodeler that binds nucleosomes to slide them along DNA. | Model for ATP-dependent chromatin remodeling. |
| SMARCA4 (BRG1) | ATPase subunit of SWI/SNF complex that binds nucleosomes to remodel chromatin. | Frequently mutated in cancer; target for synthetic lethality. |
| CTCF | Insulator protein that binds nucleosomes to organize chromatin architecture. | Key for 3D genome organization; model for loop extrusion. |
| PRC2 (EZH2) | Histone methyltransferase complex that binds nucleosomes to deposit H3K27me3. | Target in lymphoma and other cancers. |
| RCC1 | Binds nucleosomes to regulate Ran GTPase and chromatin function. | Model for nucleosome-binding in cell cycle regulation. |
| HMGB1 | Non-histone chromatin protein that binds nucleosomes to modulate accessibility. | Involved in inflammation and cancer; model for nucleosome binding. |
| PARP1 | Binds nucleosomes to facilitate DNA repair and chromatin remodeling. | Target for cancer therapy (PARP inhibitors). |
| KDM5A | Histone demethylase that binds nucleosomes to remove H3K4me3. | Implicated in cancer and intellectual disability. |
| BAF (SMARCB1) | Subunit of SWI/SNF complex that binds nucleosomes. | Mutated in rhabdoid tumors; model for chromatin remodeling. |
How Is nucleosome binding Regulated?
Nucleosome binding is regulated at multiple levels, including post-translational modifications of histones and binding proteins, ATP-dependent chromatin remodeling, and the presence of histone variants. For example, acetylation of H3K56 sensitizes nucleosomes to binding by specific proteins, as shown by Lee et al.. Pioneer transcription factors like TP53 compete with other nucleosome-binding proteins, and their binding can be modulated by nucleosome allostery [1,6]. Additionally, the composition of the nucleosome, such as the incorporation of H2A.Z or H3.3 variants, can alter binding affinities. These regulatory mechanisms ensure dynamic control of chromatin states in response to cellular signals.
nucleosome binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Cancer (Li-Fraumeni syndrome, many sporadic cancers) | TP53 knockout and point-mutant knock-in cell lines (e.g., HCT116, MCF7). |
| DEK | Acute myeloid leukemia, other cancers | DEK overexpression and knockout in hematopoietic cell lines. |
| RFX5 | Bare lymphocyte syndrome | RFX5 knockout in B-lymphoblastoid cell lines. |
| GATA3 | Breast cancer, T-cell lymphoma | GATA3 knockout and overexpression in breast cancer cell lines. |
| SMARCA4 | Rhabdoid tumors, lung cancer | SMARCA4 knockout and point-mutation knock-in in cancer cell lines. |
Nucleosome Binding in Cancer
Dysregulation of nucleosome-binding proteins is a hallmark of many cancers. TP53, a pioneer transcription factor that binds nucleosomes, is the most frequently mutated gene in human cancers, and its nucleosome binding activity is critical for tumor suppression. DEK, a nucleosome-binding protein, is overexpressed in acute myeloid leukemia and other malignancies, where it promotes H3K27 trimethylation and gene silencing. RFX5 mutations, which impair nucleosome binding and destabilization, cause bare lymphocyte syndrome, a severe immunodeficiency. These examples highlight the therapeutic potential of targeting nucleosome-binding interactions in cancer and immune disorders.
Nucleosome Binding in Developmental Disorders
Proper nucleosome binding is essential for developmental gene regulation. Mutations in chromatin remodelers such as SMARCA4 and SMARCB1, which bind nucleosomes to remodel chromatin, lead to developmental syndromes and pediatric cancers. GATA3, a nucleosome-binding transcription factor, is critical for T-cell development and mammary gland morphogenesis; its dysregulation is associated with breast cancer and immune disorders. Understanding how these proteins interact with nucleosomes provides insights into developmental pathologies.
Nucleosome Binding in Neurodegeneration
Emerging evidence links nucleosome-binding proteins to neurodegenerative diseases. For instance, HMGB1, a non-histone chromatin protein that binds nucleosomes, is implicated in neuroinflammation and neurodegeneration. PARP1, which binds nucleosomes to facilitate DNA repair, is hyperactivated in models of Parkinson's and Alzheimer's diseases, contributing to neuronal death. These findings suggest that targeting nucleosome-binding interactions may offer neuroprotective strategies.
From nucleosome binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a nucleosome-binding protein affect chromatin accessibility? | CRISPR knockout (KO) of the candidate gene followed by ATAC-seq. |
| Does a specific point mutation in a nucleosome-binding domain alter binding affinity? | Point-mutation knock-in via CRISPR prime editing or HDR. |
| Can a tagged version of the protein be used to map nucleosome binding sites? | Tagged knock-in (e.g., GFP or HA) for ChIP-seq or CUT&RUN. |
| Does overexpression of a nucleosome-binding protein drive oncogenic transformation? | Overexpression via lentiviral transduction or CRISPR activation. |
| What are the global transcriptional consequences of nucleosome-binding protein loss? | CRISPR KO followed by RNA-seq and bioinformatics analysis. |
| Can a nucleosome-binding protein be targeted for degradation? | Knock-in of a degron tag (e.g., dTAG) for inducible degradation. |
How to Study the nucleosome binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | 3D structure of protein-nucleosome complexes at near-atomic resolution | Visualizing binding interfaces and conformational changes [2,3,5]. |
| X-ray crystallography | Atomic structure of nucleosome-protein complexes | Determining high-resolution details of binding. |
| Competitive binding assay | Relative affinity of proteins for nucleosomes | Assessing pioneer factor competition. |
| ChIP-seq | Genome-wide binding sites of a protein | Mapping nucleosome-binding protein localization. |
| CUT&RUN | Genome-wide binding sites with low background | Profiling chromatin-associated proteins. |
| ATAC-seq | Chromatin accessibility | Measuring changes upon nucleosome-binding protein perturbation. |
| RNA-seq | Transcriptional changes | Assessing downstream effects of nucleosome-binding protein KO. |
| CRISPR screen | Genes required for a phenotype | Identifying novel nucleosome-binding regulators. |
Structural Biology (Cryo-EM and X-ray Crystallography)
High-resolution structural techniques such as cryo-electron microscopy (cryo-EM) and X-ray crystallography are essential for visualizing how proteins bind nucleosomes. These methods have revealed the molecular details of nucleosome binding by pioneer transcription factors, linker histones, and chromatin remodelers [1,2,3,4,5]. For example, cryo-EM structures of DEK-nucleosome complexes elucidated how DEK facilitates H3K27 trimethylation, and structures of RFX5-nucleosome complexes showed how its extended DNA binding domain destabilizes the nucleosome.
Competitive Nucleosome Binding Assays
Competitive binding assays measure the relative affinity of proteins for nucleosomes. Yu et al. used such assays to define the pioneering capabilities of TP53, showing that it can compete with linker histones for nucleosome binding. These assays are typically performed using fluorescently labeled nucleosomes and purified proteins, and can be adapted for high-throughput screening.
Genome-Wide Mapping (ChIP-seq, CUT&RUN, ATAC-seq)
Genome-wide mapping techniques identify where nucleosome-binding proteins interact with chromatin across the genome. ChIP-seq and CUT&RUN provide binding site maps for specific proteins, while ATAC-seq measures chromatin accessibility. These methods have been used to study GATA3 binding dynamics and to assess the impact of nucleosome-binding protein loss on chromatin state.
CRISPR Screens and Functional Genomics
CRISPR-based loss-of-function screens enable systematic discovery of genes required for nucleosome binding and chromatin regulation. Libraries targeting chromatin-associated genes can identify novel nucleosome-binding proteins and their roles in disease. These screens are often combined with RNA-seq or proteomics to uncover mechanisms.
How CRISPR Can Be Used to Study GO:0031491 nucleosome binding
Knockout
CRISPR knockout (KO) of genes encoding nucleosome-binding proteins is a powerful approach to study their loss-of-function phenotypes. For example, TP53 KO cell lines have been used to demonstrate its role in nucleosome binding and tumor suppression. KO models can be combined with ATAC-seq and RNA-seq to assess chromatin accessibility and transcriptional changes. EDITGENE provides custom KO cell line generation for any nucleosome-binding gene.
Point Mutation
Point mutations in nucleosome-binding domains can abrogate or alter binding affinity, providing insights into structure-function relationships. CRISPR prime editing or homology-directed repair (HDR) can introduce precise mutations. For instance, mutations in the DNA-binding domain of RFX5 impair nucleosome destabilization. EDITGENE offers point-mutation knock-in services to model disease-associated variants.
Knock-in
Knock-in of tags (e.g., GFP, HA, dTAG) allows for visualization, purification, or inducible degradation of nucleosome-binding proteins. Tagged knock-in models are valuable for ChIP-seq, CUT&RUN, and live-cell imaging. For example, a dTAG knock-in of DEK enables rapid depletion to study its role in H3K27 trimethylation. EDITGENE specializes in tagged knock-in cell models.
Overexpression
Overexpression of nucleosome-binding proteins can mimic oncogenic states or reveal gain-of-function phenotypes. Lentiviral transduction or CRISPR activation (CRISPRa) can achieve stable overexpression. DEK overexpression, for example, is observed in leukemia and promotes gene silencing. EDITGENE provides overexpression cell models for functional studies.
How EDITGENE Supports nucleosome binding Research
Researchers studying nucleosome binding-related genes often need to determine whether a candidate gene is causally involved in chromatin regulation, disease progression, or therapeutic response. This requires precise genetic models that can isolate the function of a single gene or mutation in a relevant cellular context. EDITGENE offers a comprehensive suite of CRISPR-based services to accelerate such investigations, from knockout and point-mutation models to library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for nucleosome binding research.
Frequently Asked Questions About nucleosome binding
What is nucleosome binding (GO:0031491)?
Nucleosome binding is a molecular function defined by the Gene Ontology as binding to a nucleosome, the fundamental DNA packaging unit composed of DNA wrapped around a histone core.
What genes are involved in nucleosome binding?
Key genes include TP53, GATA3, DEK, H5 (H1-5), RFX5, and many chromatin remodelers and histone variants [1,2,3,4,5,6].
How does nucleosome binding regulate gene expression?
By binding nucleosomes, proteins can alter chromatin accessibility, recruit histone-modifying enzymes, and induce structural changes that affect transcription [1,2,4,6].
What diseases are associated with nucleosome binding defects?
Dysregulation of nucleosome-binding proteins is linked to cancers (e.g., TP53, DEK), bare lymphocyte syndrome (RFX5), and developmental disorders (SMARCA4) [2,5,6,7].
What methods are used to study nucleosome binding?
Common methods include cryo-EM, X-ray crystallography, competitive binding assays, ChIP-seq, CUT&RUN, ATAC-seq, and CRISPR screens [1,2,3,4,5,6,7,8].
How can CRISPR be used to study nucleosome binding?
CRISPR knockout, point mutation, knock-in, and overexpression models enable functional interrogation of nucleosome-binding proteins in disease and development.
What is the role of TP53 in nucleosome binding?
TP53 acts as a pioneer transcription factor that binds nucleosomes to initiate chromatin opening and transcriptional activation, and its pioneering capability can be defined by competitive nucleosome binding assays [1,6].
How does DEK binding affect chromatin?
DEK binds nucleosomes and facilitates H3K27 trimethylation, a repressive histone mark, thereby promoting gene silencing.
What is the structural basis of linker histone H5 binding to nucleosomes?
Structural studies show that H5 binds the nucleosome core and linker DNA, facilitating chromatin fiber compaction.
How does RFX5 bind and destabilize nucleosomes?
The extended DNA binding domain of RFX5 binds nucleosomal DNA and induces destabilization, as revealed by structural studies.
Conclusion
Nucleosome binding (GO:0031491) is a fundamental molecular function that governs chromatin structure and gene expression. Through interactions with pioneer transcription factors, chromatin remodelers, and structural proteins, nucleosome binding controls access to the genome and influences diverse biological processes [1,2,3,4,5,6,7,8]. Dysregulation of these interactions is implicated in cancer, immunodeficiency, and developmental disorders, making them attractive targets for therapeutic intervention. Advances in structural biology and CRISPR-based functional genomics continue to unravel the mechanisms and disease relevance of nucleosome binding, offering new opportunities for drug discovery and precision medicine. EDITGENE's comprehensive CRISPR services empower researchers to dissect nucleosome binding with unprecedented precision.
References
- 1. Tan C et al.. 2020. Nucleosome allostery in pioneer transcription factor binding.. Proc Natl Acad Sci U S A 117(34):20586-20596 PMID: 32778600
- 2. Kujirai T et al.. 2025. Structural insights into how DEK nucleosome binding facilitates H3K27 trimethylation in chromatin.. Nat Struct Mol Biol 32(7):1183-1192 PMID: 39984731
- 3. Li W et al.. 2024. Structural basis for linker histone H5-nucleosome binding and chromatin fiber compaction.. Cell Res 34(10):707-724 PMID: 39103524
- 4. Ishida H et al.. 2023. Structural and Dynamic Changes of Nucleosome upon GATA3 Binding.. J Mol Biol 435(23):168308 PMID: 37805066
- 5. Xue W et al.. 2025. Structural basis of nucleosome binding and destabilization by the extended DNA binding domain of RFX5.. Nucleic Acids Res 53(14) PMID: 40744500
- 6. Yu X et al.. 2019. Defining TP53 pioneering capabilities with competitive nucleosome binding assays.. Genome Res 29(1):107-115 PMID: 30409772
- 7. Tan S et al.. 2011. Nucleosome structural studies.. Curr Opin Struct Biol 21(1):128-36 PMID: 21176878
- 8. Lee J et al.. 2019. How Protein Binding Sensitizes the Nucleosome to Histone H3K56 Acetylation.. ACS Chem Biol 14(3):506-515 PMID: 30768236
